Showing results (291-300 of 326) with videos related to
Sort By:
Pageof 33
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroYasuhiro Koh, Hirotomo Nakata, Kenji Maeda, et al.Retrovirology|June 27, 2013
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdAEleftherios Michailidis, Emily M Ryan, Atsuko Hachiya, et al.Journal of Medicinal Chemistry|August 18, 2006
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistanceArun K Ghosh, Perali Ramu Sridhar, Sofiya Leshchenko, et al.Antimicrobial Agents and Chemotherapy|October 9, 2013
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosineKaren A Kirby, Eleftherios Michailidis, Tracy L Fetterly, et al.Journal of Hepatology|December 17, 2020
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBVNobuyo Higashi-Kuwata, Sanae Hayashi, Hiroki Kumamoto, et al.The Journal of Infectious Diseases|September 27, 2023
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched AnalysisShohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.Antimicrobial Agents and Chemotherapy|April 23, 2014
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIVRavikiran S Yedidi, Harisha Garimella, Manabu Aoki, et al.World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.The Journal of Biological Chemistry|June 28, 2014
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsEleftherios Michailidis, Andrew D Huber, Emily M Ryan, et al.Hepatology (Baltimore, Md.)|July 1, 2015
4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virusYuki Takamatsu, Yasuhito Tanaka, Satoru Kohgo, et al.Pageof 33